Skip to main content

GENERATION DE NUEVAS HERRAMIENTAS IMMUNOTERAPEUTICAS PARA EL TRATAMIENTO DE LEUCEMIAS T-ALL

PID2019-105404RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9+ tumors

  • Santamaría, Silvia
  • Delgado, Marisa
  • Botas, Marta
  • Castellano, Eva
  • Corraliza-Gorjon, Isabel
  • Lafuente, Paloma
  • Muñoz-Calleja, Cecilia
  • Toribio, María Luisa
  • Kremer, Leonor
  • García-Sanz, José A.
18 p.-7 fig.-2 tab., Relapsed or refractory T acute lymphoblastic leukemia (T-ALL) still carries poor prognosis. Aiming to improve outcomes, the therapeutic potential of an anti-CCR9 monoclonal antibody (mAb 92R), targeting the human chemokine-receptor CCR9 is analyzed on orthotopic xenotransplants. 92R mAb treatment of mice carrying human CCR9+ T-ALL cell lines or primary T cell leukemias inhibits tumor growth and increases survival. The therapeutic effects of 92R are specific and synergize with chemotherapeutic agents increasing survival. Furthermore, 92R decreases size of non-hematopoietic tumors with a forced CCR9 expression and of solid tumors generated by the pancreatic adenocarcinoma cell line AsPC-1. In addition, a humanized version of 92R mAb (Srb1) is also able to inhibit growth of CCR9+ T-ALL tumor cells in vivo, increasing survival 2.66-fold. Finally, 92R mAb prevents liver accumulation of infiltrates and reduces tumor cell numbers in already formed infiltrates. Thus, the humanized version of 92R mAb (Srb1), displays therapeutic potential for CCR9+ tumor treatment and might represent one of the first therapeutic antibodies for precision medicine on T-ALL patients., The work in the author’s laboratories was partially supported by grants from the PN2014-A from the ISCIII (PI14/00703, co-financed by FEDER funds from the EU, Operative program on Intelligent Growth 2014-2020, to LK); the Spanish Ministry of Economy, Industry and Competitiveness (RTC-2015-3786-1 to LK and JG-S), co-financed by FEDER funds from the EU and from the Spanish Ministry of Science and Innovation (PID2019-105404RB-I00 to JAGS and LK financed by MCIN/AEI/10.13039/501100011033). As well as the CSIC (PIE-201420E109 and PIE-201720E092, to LK)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Editorial: The effects of chemotherapy towards the tumor microenvironment

  • Abu, Nadiah
  • Turdo, Alice
  • García-Sanz, José A.
3 p.-1 fig., The work in the author’s laboratories was partially supported by grants from the Spanish Ministry of Science and Innovation (PID2019-105404RB-I00 financed by MCIN/AEI/10.13039/501100011033) to JAGS., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Stemming tumoral growth: A matter of grotesque organogenesis

  • Merino, Marisa M.
  • García-Sanz, José A.
The earliest metazoans probably evolved from single-celled organisms which found the colonial system to be a beneficial organization. Over the course of their evolution, these primary colonial organisms increased in size, and division of labour among the cells became a remarkable feature, leading to a higher level of organization: the biological organs. Primitive metazoans were the first organisms in evolution to show organ-type structures, which set the grounds for complex organs to evolve. Throughout evolution, and concomitant with organogenesis, is the appearance of tissue-specific stem cells. Tissue-specific stem cells gave rise to multicellular living systems with distinct organs which perform specific physiological functions. This setting is a constructive role of evolution; however, rebel cells can take over the molecular mechanisms for other purposes: nowadays we know that cancer stem cells, which generate aberrant organ-like structures, are at the top of a hierarchy. Furthermore, cancer stem cells are the root of metastasis, therapy resistance, and relapse. At present, most therapeutic drugs are unable to target cancer stem cells and therefore, treatment becomes a challenging issue. We expect that future research will uncover the mechanistic “forces” driving organ growth, paving the way to the implementation of new strategies to impair human tumorigenesis., M.M.M. was supported by Swiss National Science Foundation (SNSF) (SystemsX.ch, Transition Postdoc Fellowship) and Novartis Foundation Fellowships. The work in JAGS’ laboratory is supported by the Spanish Ministry of Science and Innovation PID2019-105404RB-I00, financed by MCIN/AEI/10.13039/501100011033., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Therapeutic Monoclonal Antibodies against Cancer: Present and Future

  • Delgado, Marisa
  • Garcia-Sanz, Jose A.
A series of monoclonal antibodies with therapeutic potential against cancer have been generated and developed. Ninety-one are currently used in the clinics, either alone or in combination with chemotherapeutic agents or other antibodies, including immune checkpoint antibodies. These advances helped to coin the term personalized medicine or precision medicine. However, it seems evident that in addition to the current work on the analysis of mechanisms to overcome drug resistance, the use of different classes of antibodies (IgA, IgE, or IgM) instead of IgG, the engineering of the Ig molecules to increase their half-life, the acquisition of additional effector functions, or the advantages associated with the use of agonistic antibodies, to allow a broad prospective usage of precision medicine successfully, a strategy change is required. Here, we discuss our view on how these strategic changes should be implemented and consider their pros and cons using therapeutic antibodies against cancer as a model. The same strategy can be applied to therapeutic antibodies against other diseases, such as infectious or autoimmune diseases., The work in the author’s laboratory is supported by the Spanish Ministry of Science and Innovation PID2019-105404RB-I00, financed by MCIN/AEI/10.13039/501100011033., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Enhancing magnetic hyperthermia at the cell membrane by anchoring 92R-functionalized magnetic nanoparticles to low-endocytic CCR9 surface receptors

  • Egea-Benavente, David
  • Corraliza-Gorjón, Isabel
  • Zanten, Thomas S. van
  • Morales, María Del Puerto
  • Kremer, Leonor
  • Barber, Domingo F.
The data that support the findings of this study are available from the corresponding author upon reasonable request., Magnetic hyperthermia therapy (MHT) is a promising cancer treatment that has demonstrated efficacy in phase I and II clinical trials for glioblastoma and prostate cancer. MHT relies on heat generated by magnetic nanoparticles (MNPs) when exposed to alternating magnetic fields (AMFs). The heat output depends not only on the intrinsic properties of MNPs but also on extrinsic factors such as the extracellular and intracellular environments. Aggregation of MNPs under certain conditions can significantly reduce therapeutic efficiency. To overcome this limitation, we present a strategy to enhance MHT by modulating MNP-cell interactions. We functionalized dimercaptosuccinic acid (DMSA)-coated MNPs with the 92R antibody (DMSA-MNPs@92R), which selectively binds to the low-internalization chemokine receptor CCR9, overexpressed in certain tumors. Exposure of CCR9+ MOLT-4 cells to DMSA-MNPs@92R under AMFs resulted in enhanced tumor cell death. Our approach enables spatially controlled binding, maintaining MNPs in a less-aggregated state and at an optimal distance from the cell membrane to maximize heat generation. Mechanistic analysis confirmed that cytotoxicity is driven by localized hyperthermia at the subcellular level rather than a macroscopic temperature increase. These findings underscore the potential of controlled MNPs-cell interactions to improve in vitro MHT performance and open an interesting avenue for enhancing therapeutic efficacy., D.E.-B. is a predoctoral fellow at the Molecular Biosciences Program of the Universidad Autónoma de Madrid supported by the Spanish Ministry of Science and Innovation through a FPI Contract (PRE2018-084189). This work was supported in part by the Spanish Ministry of Science and Innovation through Grant SAF-2017-82223-R (to D.F.B., funded by MCIN/AEI/10.13039/501100011033 and by the ERDF a way of making Europe), PID2019-105404RB-I00 (to L.K., funded by MCIN/AEI/10.13039/501100011033), PID-2020-112685RB-I00 (to D.F.B., funded by MCIN/AEI/10.13039/501100011033), PID2023-150170OB-I00 (to M.P.M., funded by MCIN/AEI/10.13039/501100011033), and PID-2023-146212OB-I00 (to D.F.B, funded by MCIN/AEI/10.13039/501100011033 and by the ERDF, EU). This work was also supported by the CSIC Grant PIE-202320E096 (to L.K.). T.S.v.Z. acknowledges the Severo Ochoa Program for Centres of Excellence, Grant CEX2023-001286-S funded by MICIU/AEI/10.13039/501100011033. The Centro Nacional de Biotecnología (CNB-CSIC) a Severo Ochoa Center of Excellence (CEX2023-001386-S) funded by MICIU/AEI /10.13039/501100011033. The groups of D.F.B. and M.P.M. are part of the “Nanotechnology in Translational Hyperthermia” Network supported by the Spanish Ministry of Science and Innovation (HIPERNANO, RED2018-102626-T, funded by MCIN/AEI/10.13039/501100011033). This research work was performed in the framework of the Nanomedicine CSIC HUB and the CSIC Cancer HUB., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2023-001286-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2023-001386-S)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Enhancing Magnetic Hyperthermia at the Cell Membrane by Anchoring 92R‐Functionalized Magnetic Nanoparticles to Low‐Endocytic CCR9 Surface Receptors

  • Egea-Benavente, David
  • Corraliza-Gorjón, Isabel
  • Van Zanten, Thomas S.
  • Morales, María del Puerto
  • Kremer, Leonor
  • Barber, Domingo F.
Magnetic hyperthermia therapy (MHT) is a promising cancer treatment that has demonstrated efficacy in phase I and II clinical trials for glioblastoma and prostate cancer. MHT relies on heat generated by magnetic nanoparticles (MNPs) when exposed to alternating magnetic fields (AMFs). The heat output depends not only on the intrinsic properties of MNPs but also on extrinsic factors such as the extracellular and intracellular environments. Aggregation of MNPs under certain conditions can significantly reduce therapeutic efficiency. To overcome this limitation, we present a strategy to enhance MHT by modulating MNP-cell interactions. We functionalized dimercaptosuccinic acid (DMSA)-coated MNPs with the 92R antibody (DMSA–MNPs@92R), which selectively binds to the low-internalization chemokine receptor CCR9, overexpressed in certain tumors. Exposure of CCR9+ MOLT-4 cells to DMSA–MNPs@92R under AMFs resulted in enhanced tumor cell death. Our approach enables spatially controlled binding, maintaining MNPs in a less-aggregated state and at an optimal distance from the cell membrane to maximize heat generation. Mechanistic analysis confirmed that cytotoxicity is driven by localized hyperthermia at the subcellular level rather than a macroscopic temperature increase. These findings underscore the potential of controlled MNPs-cell interactions to improve in vitro MHT performance and open an interesting avenue for enhancing therapeutic efficacy.